-
公开(公告)号：US20160264536A1
公开(公告)日：2016-09-15
申请号：US15031505
申请日：2014-10-22
发明人： Masaki SETO , Yoshihiro BANNO , Toshihiro IMAEDA , Yuichi KAJITA , Tomoko ASHIZAWA , Masanori KAWASAKI , Shinji NAKAMURA , Satoshi MIKAMI , Izumi NOMURA , Takahiko TANIGUCHI , Shogo MARUI
IPC分类号： C07D277/56 , C07D403/12 , C07D239/28 , C07D403/04 , C07D239/47 , C07D239/36 , C07D239/52 , C07D241/24 , C07D498/08 , C07D413/04 , C07D405/04 , C07D401/04 , C07D417/04 , C07D409/04 , C07D401/12 , C07D239/42
CPC分类号： C07D277/56 , C07D239/28 , C07D239/36 , C07D239/42 , C07D239/47 , C07D239/48 , C07D239/52 , C07D239/54 , C07D239/56 , C07D241/24 , C07D241/26 , C07D277/20 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D409/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D498/04 , C07D498/08
摘要： The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
摘要翻译： 其中每个符号如说明书中所述或其盐。
-
公开(公告)号：US20190040010A1
公开(公告)日：2019-02-07
申请号：US16052967
申请日：2018-08-02
发明人： Yuichi Kajita , Satoshi MIKAMI , Yuhei MIYANOHANA , Tatsuki KOIKE , Masaki DAINI , Norio OHYABU , Masaki OGINO , Kohei TAKEUCHI , Yoshiteru ITO , Norihito TOKUNAGA , Takahiro SUGIMOTO , Tohru MIYAZAKI , Tsuneo ODA , Yasutaka HOASHI , Yasushi HATTORI , Keisuke IMAMURA
IPC分类号： C07D211/56 , C07D401/10 , C07D401/06 , C07D207/14 , C07D405/10 , C07D417/06 , C07D405/12 , C07D413/06 , C07D401/14 , C07D205/04 , C07D403/06 , C07D417/14 , A61P25/00
摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
-
公开(公告)号：US20170129887A1
公开(公告)日：2017-05-11
申请号：US15264213
申请日：2016-09-13
发明人： Satoshi MIKAMI , Shinji NAKAMURA , Tomoko ASHIZAWA , Shigekazu SASAKI , Takahiko TANIGUCHI , Izumi NOMURA , Masanori KAWASAKI
IPC分类号： C07D471/04 , A61K31/555 , A61K31/498 , A61K9/20 , C07F7/18
CPC分类号： C07D471/04 , A61K9/20 , A61K31/498 , A61K31/555 , C07D519/00 , C07F7/1804
摘要： The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20220289679A1
公开(公告)日：2022-09-15
申请号：US17630442
申请日：2020-07-28
发明人： Yuta TANAKA , Yuta TANAKA , Keiko KAKEGAWA , Takahito KASAHARA , Fumiaki KIKUCHI , Takeshi YAMAMOTO , Tomohiro OHASHI , Zenichi IKEDA , Florian PUENNER , Minoru NAKAMURA , Kazuaki TAKAMI , Masataka MURAKAMI , Masaki DAINI , Masaki SETO , Satoshi MIKAMI , Minoru SASAKI
IPC分类号： C07D213/82 , C07D401/12 , C07D471/04 , C07D413/12 , C07D405/14 , C07D401/14 , C07D237/14 , C07D405/12
摘要： The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.-
公开(公告)号：US20200247801A1
公开(公告)日：2020-08-06
申请号：US16753630
申请日：2018-10-04
IPC分类号： C07D471/04 , C07D413/10 , C07D407/12 , C07D413/14
摘要： The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
-
公开(公告)号：US20200017444A1
公开(公告)日：2020-01-16
申请号：US16577449
申请日：2019-09-20
发明人： Yuichi KAJITA , Satoshi MIKAMI , Yuhei MIYANOHANA , Tatsuki KOIKE , Masaki DAINI , Norio OYABU , Masaki OGINO , Kohei TAKEUCHI , Yoshiteru ITO , Norihito TOKUNAGA , Takahiro SUGIMOTO , Tohru MIYAZAKI , Tsuneo ODA , Yasutaka HOASHI , Yasushi HATTORI , Keisuke IMAMURA
IPC分类号： C07D211/56 , A61P25/00 , C07D205/04 , C07D207/14 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/06 , C07D405/10 , C07D405/12 , C07D413/06 , C07D417/06 , C07D417/14 , C07D211/36 , C07D405/06
摘要： The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
-
公开(公告)号：US20190300536A1
公开(公告)日：2019-10-03
申请号：US16366710
申请日：2019-03-27
发明人： Yuya OGURO , Shigemitsu MATSUMOTO , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Satoshi MIKAMI , Masaki SETO , Shinji MORIMOTO , Shinji NAKAMURA , Sachie TAKASHIMA , Masataka MURAKAMI , Masaki DAINI , Makoto KAMATA , Minoru NAKAMURA , Yasufumi WADA , Hiroyuki KAKEI , Kazuaki TAKAMI , Taisuke TAWARAISHI , Jumpei AIDA , Kouichi IWANAGA , Satoshi YAMAMOTO
IPC分类号： C07D487/04 , C07D471/04 , A61K9/20 , A61K9/48
摘要： The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
-
公开(公告)号：US20230348435A1
公开(公告)日：2023-11-02
申请号：US17999505
申请日：2021-05-20
发明人： Tomoaki HASUI , Satoshi MIKAMI , Toru YAMASHITA , Shinji NAKAMURA , Shinji MORIMOTO , Toshihiro IMAEDA , Kazuaki TAKAMI , Masaki DAINI , Hiroyuki KAKEI , Minoru NAKAMURA , Fumie YAMAGUCHI , Chunxiang WANG , Sachie TAKASHIMA , Shogo HASHIZUME
IPC分类号： C07D403/06 , A61K45/06 , C07D413/14 , C07D403/14 , C07D401/14 , C07D405/14
CPC分类号： C07D403/06 , A61K45/06 , C07D413/14 , C07D403/14 , C07D401/14 , C07D405/14
摘要： The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-(OH-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).
-
公开(公告)号：US20220089525A1
公开(公告)日：2022-03-24
申请号：US17310164
申请日：2020-01-23
发明人： Yuya OGURO , Makoto KAMATA , Satoshi MIKAMI , Shinji MORIMOTO , Sachie TAKASHIMA , Masaki DAINI , Osamu KUBO , Fumiaki KIKUCHI , Akinori TOITA , Florian PUENNER , Takahito KASAHARA , Masataka MURAKAMI , Shuhei IKEDA , Fumie YAMAGUCHI , Minoru NAKAMURA , Takafumi YUKAWA
IPC分类号： C07C255/60 , C07D213/82 , C07D401/12 , C07D409/12 , A61P25/06 , A61P25/24 , A61P25/28 , A61P29/00
摘要： A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
-
公开(公告)号：US20210332053A1
公开(公告)日：2021-10-28
申请号：US17201878
申请日：2021-03-15
发明人： Yuya OGURO , Shigemitsu MATSUMOTO , Takeshi WAKABAYASHI , Norihito TOKUNAGA , Taku KAMEI , Mitsuhiro ITO , Satoshi MIKAMI , Masaki SETO , Shinji MORIMOTO , Shinji NAKAMURA , Sachie TAKASHIMA , Masataka MURAKAMI , Masaki DAINI , Makoto KAMATA , Minoru NAKAMURA , Yasufumi WADA , Hiroyuki KAKEI , Kazuaki TAKAMI , Taisuke TAWARAISHI , Jumpei AIDA , Kouichi IWANAGA , Satoshi YAMAMOTO
IPC分类号： C07D487/04 , A61K9/20 , A61K9/48 , C07D471/04 , A61P25/00
摘要： The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.036 秒)
